References: 1. Ahmed KA, Stallworth DG, Kim Y, Johnstone PAS, Harrison LB, Caudell JJ, et al: Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:434–441, 2016
2. Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, et al: Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 133:331–338, 2017
3. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, et al: Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125:80–88, 2017
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al: Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med 373:1627–1639, 2015
5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med 373:123–135, 2015
6. Brown PD, Jaeckle K, Ballman K V., Farace E, Cerhan JH, Anderson SK, et al: Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. Jama 316:401–409, 2016
7. Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al: Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer. J Clin Oncol 35:3867–3876, 2017
8. Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, et al: Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol 100:916–925, 2018
9. Cohen-Inbar O, Shih H-H, Xu Z, Schlesinger D, Sheehan JP: The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg 127:1007–1014, 2017
10. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–51, 1997
11. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al: Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983, 2016
12. Gray RJ: A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat 16:1141–1154, 1988
13. Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, et al: Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol 13:550–558, 2018
14. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al: Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–75, 2015
15. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS: Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227–233, 2012
16. Kotecha R, Kim JM, Miller JA, Juloori A, Chao ST, Murphy ES, et al: The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis. Neuro Oncol: epub ahead of print 2019
17. Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quiñones-Hinojosa A, Zaorsky NG, et al: Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiother Oncol 130:104–112, 2018
18. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al: Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol 16:270–278, 2015
19. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al: Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. J Clin Oncol 30:2046–2054, 2012
20. Martin A, Cagney D, Catalano P, Alexander B, Redig A, Schoenfeld J, et al: Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncol 4:1123–1124, 2018
21. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al: Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23:191–5, 2013
22. Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA, et al: Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. Int J Radiat Oncol 96:1060–1069, 2016
23. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al: Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol 40:444–450, 2017
24. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al: Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 375:1823–1833, 2016
25. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375:1823–1833, 2016
26. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265, 2017
27. Salvetti DJ, Nagaraja TG, McNeill IT, Xu Z, Sheehan J: Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain: clinical article. J Neurosurg 116:1250–1257, 2013
28. Sharabi AB, Lim M, DeWeese TL, Drake CG: Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498–e509, 2015
29. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903, 2017
30. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD: Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:899–906, 2013
31. Singh C, Qian JM, Yu JB, Chiang VL: Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. J Neurosurg 15:1–6, 2019
32. Singh R, Zhou Z, Tisnado J, Haque S, Peck KK, Young RJ, et al: A novel magnetic resonance imaging segmentation technique for determining diffuse intrinsic pontine glioma tumor volume. J Neurosurg Pediatr 18:565–572, 2016
33. Soria J-C, Marabelle A, Brahmer JR, Gettinger S: Immune Checkpoint Modulation for Non-Small Cell Lung Cancer. Clin Cancer Res 21:2256–2262, 2015